Sinonasal melanomas are rare neoplasms with poor prognosis that may harbor KIT and NRAS genes mutations. Molecular alterations represent possible targets of tailored therapeutic approaches. We describe the case of a 74-year-old patient with primary melanoma of the nasal cavity. Mutational analysis of KIT demonstrated a point missense mutation D820G in exon 17. This represents, to our knowledge, the first case of sinonasal melanoma harboring this specific KIT mutation. Although KIT mutations confer sensibility to thyrosine-kinase inhibitor, it has been proved that this is strongly dependent on the region in which this alteration occurs. Thus it seems very important to perform an accurate gene mutational analysis to provide a biological rationale to the tailored therapy.
S inonasal melanomas (SNM) originate from mucosa of nasal cavity and paranasal sinuses and represent <1% of all melanomas. 1 Patients with SNM have a poor prognosis and low 5-year survival rates. At molecular level, mucosal melanomas represent a specific subgroup of lesions, generally characterized by mutations in KIT and NRAS genes. [2] [3] [4] Mutations in the BRAF gene, frequently detected in nonchronically sun-damaged skin, rarely occurs in these malignancies. Although the possibility to treat melanoma patients with conventional chemotherapy has been discouraging for many years, the molecular characterization of both skin and mucosal melanomas is going to have an important clinical impact in the era of the molecular targeted therapy. Currently such information allows to explore novel and tailored therapeutic approaches which are based on a strong biological rationale. 4 KIT is a type III transmembrane receptor tyrosine kinase (TK). Activating mutations in exons encoding the juxtamembrane receptor domain are frequently found in gastrointestinal stromal tumors (GISTs) and represent indeed, the putative targets for thyrosine-kinase inhibitors (TKIs) as imatinib mesylate. 5 In KIT-mutated melanoma the therapeutic effect of KIT inhibitors has been proved in experimental tumor models in vitro and in vivo underlying the importance of looking for KIT mutations especially in mucosal and acral melanoma. 6, 7 We describe here a case of 74-year-old man presenting with SNM and harboring the unusual primary mutation D820G in exon 17 of KIT gene. This represents to our knowledge the first case of SNM reported in literature with this specific KIT mutation.
CASE REPORT
A 74-year-old man was referred to Ear-Nose-Throat unit of our hospital for bleeding. The nuclear magnetic resonance (NMR) showed a pathologic tissue heterogeneously hyperintense on T1-weighted images (T1WI), iso-hyperintense in T2WI, with homogeneous enhancement after contrast medium in the right nasal cavity (Fig. 1A) . The lesion extended cranially toward the right nasolacrimal canal. The computed tomography with contrast showed a suspicious extension in the orbital fat. A surgical biopsy was performed and a black polypoid tissue fragment of about 3 cm was submitted for histologic examination. Histologically, the tumor consisted of a proliferation of epithelioid cells with high mitotic rate, melanin pigmentation in about 50% of the lesion, associated to necrosis and superficial ulceration (Fig. 1C ). Tumor cells expressed S-100 and HMB-45. Moreover, about 30% of neoplastic cells showed plasma membrane and cytoplasmic immunostaining for C-KIT (CD117).
Mutational analysis of BRAF exon 15 end KIT exon 9, 11, 13, and 17 were performed using the following oligonucleotides:
All PCR products were sequenced bidirectionally using the Big Dye Terminator chemistry and Applied Biosystems Automated 3130 DNA Analyzer (Life Technology). No mutations were detected in the BRAF gene, whereas a point missense mutation D820G in KIT exon 17 (GeneBank NM000222.2, c.2459 A >G; p.D820G) was identified (Fig. 1D ). The mutation was confirmed on a duplicate PCR amplification and sequencing. After histologic diagnosis the patient received an intensitymodulated radiation therapy for a total dose of 66 Gy in 30 fractions of 2.2 Gy on the right nasal cavity and on the medial and inferior portion of orbital cavity respecting constrain for eye, optic nerve, and optic chiasm. During the treatment the patient was submitted to daily cone-beam-computed tomography for control of position performing an image-guided radiation therapy (IGRT). NMR control performed 3 months after RT showed complete remission (Fig. 1B) .
DISCUSSION
We report the first case of SNM harboring the mutation D820G in exon 17 of KIT gene. This specific mutation to our knowledge has never been reported in SNM either in large studies or single case report (Table 1). KIT is a type III transmembrane TK receptor which physiologically plays an important role in development and survival of melanocytes, Cajal cells, erythrocytes, mast cells, and germ cells. KIT mutations have been reported in several neoplasms other than melanomas: GIST, myeloid leukemia, mastocytosis, and seminoma. Frequency and mutation hotspots of KIT gene vary in different tumors. In GIST and melanomas, mutations mainly occur in exon 9 (encoding the extracellular domain), in exon 11 (encoding the juxtamembrane domain), in exon 13 (encoding the TK I domain), whereas in leukemia, mastocytosis and germ cell tumors occur in exon 17 (encoding the TK II domain). 5, 14 KIT mutations represent the putative therapeutic target for TK inhibitors, however, only specific KIT alterations are truly oncogenic and predictive of an effective therapeutic target. Mutations affecting the juxtamembrane region of the receptor result in its constitutive activation and are particularly responsive to imatinib, whereas mutations in the kinase domain I and II may confer resistance. 15 The mutation D820G in exon 17 of KIT causes a substitution of an aspartate with glycine. It represents an activating mutation and has been reported as a primary mutation in germ cell tumors and mast cell neoplasm. 16, 17 In GIST, D820G mutation has been reported as a secondary gene mutation responsible for acquired resistance of neoplasm to imatinib. 15, 18 This mutation has not been reported before in mucosal melanomas (Table 1) .
In mucosal melanomas, KIT mutations rate vary according to anatomic sites showing significant higher frequency in vulvar and anal melanoma while it is relatively rare in SNM. 10, 13 In particular, Zebary et al 8 investigated the largest series of SNM (56 cases) for KIT mutation (exon 11, 13, and 17) and found only 2 cases mutated (4%) both in exon 11. Shoenewolf et al 10 investigated 19 SNM. KIT sequencing analysis of exons 9, 11, 13, 17, and 18 was performed in 12 of 19 SNM cases and except for a polymorphism in codon 862, not KIT mutations were reported. Colombino et al 11 investigated 11 SNM for the presence of KIT and BRAF mutations. They found no KIT mutations in any case except for a polymorphism in codon 862, whereas found BRAF mutation V600E in 4 of 11 cases. Turri-Zanoni and colleagues looked for KIT genes mutations (exons 9, 11, 13, 17, and 18) in a series of 32 SNM. They found KIT mutation in 4 of 32 cases, 3 in exon 11 and 1 in exon 18. 9 Carvajal and colleagues investigated 295 acral, mucosa, and chronically sun-damaged skin for KIT mutations/amplification. Two 5 cases of SNM investigated harbored a point mutation in KIT exon 9 and exon 13, respectively. 4 Data from clinical trials with TKI therapy in KIT-mutated melanomas showed that primary exon 17 mutations correlate with a poor therapeutic response, compared with KIT mutations in exon 11 and 9 confirming that response to imatinib mesylate is strongly dependent on the type of KIT mutation and in particular on the specific region of the receptor in which this alteration occurs. 3, 12 The case reported herein shows a consistent expression of KIT protein in about 30% of the tumor cells. KIT expression has been largely investigated in mucosal melanoma. However, several studies proved KIT expression is not related to KIT gene mutation. 10, 19 In our case the patient has been treated with local radiotherapy and not with systemic TKI therapy. Considering the data available so far, the presence of D820G mutation may not confer a real advantage to imatinib mesylate therapy. 4, 12 However, it still remains uncertain if mutations conferring imatinib resistance can respond to TKIs of second generation. 20 In conclusion, considering the social costs of the molecular-targeted therapies available so far for cancer treatment, it seems very important to perform an accurate gene mutational analysis for each candidate tumor, to provide a biological rationale to the tailored therapy.
In the main time accurate structural and functional studies on putative target molecules like TK receptors, which are biologically critical for cancer, become imperative. The discovery of molecular alterations, which confer resistance, could prevent a true therapeutic failure. 
